[{"id":"c3ccbe27-3d9e-4190-a952-e531da2607f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890093","created_at":"2021-05-18T12:01:54.563Z","updated_at":"2025-02-25T13:49:09.588Z","phase":"Phase 1/2","brief_title":"Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT04890093","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vincristine • locnartecan (PEN-866)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-20"},{"id":"eda22fa5-a154-4718-aaaf-d2fb8460e402","acronym":"","url":"https://clinicaltrials.gov/study/NCT02721459","created_at":"2021-01-18T13:18:50.231Z","updated_at":"2025-02-25T16:30:48.412Z","phase":"Phase 1","brief_title":"XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma","source_id_and_acronym":"NCT02721459","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib) • XL888"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/07/2016","start_date":" 09/07/2016","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-07"},{"id":"2ede59b9-f8a7-4ea2-873c-71d302f69b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01560416","created_at":"2021-01-18T06:36:36.789Z","updated_at":"2024-07-02T16:35:06.809Z","phase":"Phase 2","brief_title":"Fulvestrant With or Without Ganetespib in HR+ Breast Cancer","source_id_and_acronym":"NCT01560416","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • ganetespib (ADX-1612)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2012","start_date":" 05/01/2012","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-30"},{"id":"fab06802-4790-49ac-8add-eadb832847c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01167114","created_at":"2021-01-18T04:39:14.334Z","updated_at":"2024-07-02T16:35:30.627Z","phase":"Phase 2","brief_title":"STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer","source_id_and_acronym":"NCT01167114","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HSP90AA1","pipe":"","alterations":" ","tags":["HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 04/01/2017","study_completion_date":" 04/01/2017","last_update_posted":"2023-11-02"},{"id":"3c9529ef-684d-40e0-abc9-1500bd742be6","acronym":"BrUOG 387","url":"https://clinicaltrials.gov/study/NCT05655598","created_at":"2022-12-19T14:58:37.717Z","updated_at":"2024-07-02T16:35:36.916Z","phase":"Phase 1","brief_title":"TAS-116 Plus Palbociclib in Breast and Rb-[] Cancer","source_id_and_acronym":"NCT05655598 - BrUOG 387","lead_sponsor":"Brown University","biomarkers":" HER-2","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Jeselhy (pimitespib)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/12/2023","start_date":" 09/12/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-09-14"},{"id":"941b1153-fb94-4360-9c39-d0685da9af97","acronym":"","url":"https://clinicaltrials.gov/study/NCT01393509","created_at":"2021-01-18T05:43:22.326Z","updated_at":"2024-07-02T16:35:52.184Z","phase":"Phase 1","brief_title":"The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT01393509","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" JAK2 • CD4","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zelavespib intravenous (PU-H71 IV)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 07/06/2011","start_date":" 07/06/2011","primary_txt":" Primary completion: 03/23/2023","primary_completion_date":" 03/23/2023","study_txt":" Completion: 03/23/2023","study_completion_date":" 03/23/2023","last_update_posted":"2023-03-28"},{"id":"5e8d91ea-f7f3-439a-aea4-8b3ad3fa4f77","acronym":"","url":"https://clinicaltrials.gov/study/NCT01657591","created_at":"2021-01-18T07:08:59.902Z","updated_at":"2024-07-02T16:35:57.422Z","phase":"Phase 1","brief_title":"Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma","source_id_and_acronym":"NCT01657591","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • XL888"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 07/27/2012","start_date":" 07/27/2012","primary_txt":" Primary completion: 09/20/2016","primary_completion_date":" 09/20/2016","study_txt":" Completion: 09/21/2021","study_completion_date":" 09/21/2021","last_update_posted":"2023-01-19"},{"id":"4c23fea7-185d-4aea-b8bc-904da5a38f96","acronym":"","url":"https://clinicaltrials.gov/study/NCT03221400","created_at":"2021-01-18T15:53:56.456Z","updated_at":"2024-07-02T16:36:16.953Z","phase":"Phase 1/2","brief_title":"PEN-866 in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT03221400","lead_sponsor":"Tarveda Therapeutics","biomarkers":" HSP90AA1","pipe":"","alterations":" ","tags":["HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Zejula (niraparib) • irinotecan • leucovorin calcium • locnartecan (PEN-866)"],"overall_status":"Recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 08/29/2017","start_date":" 08/29/2017","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-02-17"},{"id":"2b53c85f-055b-4401-b086-8ffe8c25b04d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03166085","created_at":"2021-01-18T15:36:35.642Z","updated_at":"2024-07-02T16:36:19.332Z","phase":"Phase 1b","brief_title":"PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer","source_id_and_acronym":"NCT03166085","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • zelavespib intravenous (PU-H71 IV)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 12/14/2021","primary_completion_date":" 12/14/2021","study_txt":" Completion: 12/14/2021","study_completion_date":" 12/14/2021","last_update_posted":"2021-12-20"},{"id":"8c103644-1176-42a6-848c-96531a290601","acronym":"","url":"https://clinicaltrials.gov/study/NCT01579994","created_at":"2021-01-18T06:43:34.807Z","updated_at":"2024-07-02T16:36:36.694Z","phase":"Phase 1","brief_title":"Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers","source_id_and_acronym":"NCT01579994","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement • ALK translocation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 04/16/2012","start_date":" 04/16/2012","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2020-12-30"},{"id":"556b24f4-a540-4e32-bed4-b81cc50ddf9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00526045","created_at":"2021-01-18T01:54:04.948Z","updated_at":"2024-07-02T16:36:37.192Z","phase":"Phase 1/2","brief_title":"Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT00526045","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 overexpression • HER-2 amplification","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 07/01/2007","start_date":" 07/01/2007","primary_txt":" Primary completion: 04/01/2012","primary_completion_date":" 04/01/2012","study_txt":" Completion: 04/01/2012","study_completion_date":" 04/01/2012","last_update_posted":"2020-12-17"},{"id":"fe2ea4e8-cbb7-4bab-8f68-0897e6024013","acronym":"","url":"https://clinicaltrials.gov/study/NCT01271920","created_at":"2021-01-18T05:08:38.739Z","updated_at":"2024-07-02T16:36:37.636Z","phase":"Phase 1/2","brief_title":"Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab","source_id_and_acronym":"NCT01271920","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 10/01/2013","study_completion_date":" 10/01/2013","last_update_posted":"2020-12-08"},{"id":"cfc79c3c-37ef-4a18-bf47-b2fdd946273f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01784640","created_at":"2021-01-18T07:52:45.292Z","updated_at":"2025-02-25T15:40:37.769Z","phase":"Phase 1","brief_title":"Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01784640","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/31/2014","start_date":" 01/31/2014","primary_txt":" Primary completion: 10/11/2018","primary_completion_date":" 10/11/2018","study_txt":" Completion: 10/11/2018","study_completion_date":" 10/11/2018","last_update_posted":"2020-09-03"},{"id":"6606638f-85e0-45a0-a871-7812ab59024d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00878423","created_at":"2021-01-18T03:21:30.390Z","updated_at":"2024-07-02T16:36:51.244Z","phase":"Phase 1","brief_title":"Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors","source_id_and_acronym":"NCT00878423","lead_sponsor":"Astex Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e onalespib (AT13387)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2020-01-18"},{"id":"73343190-c6f4-42f9-9309-f426699e9323","acronym":"","url":"https://clinicaltrials.gov/study/NCT02965885","created_at":"2021-01-18T14:34:41.227Z","updated_at":"2024-07-02T16:36:55.044Z","phase":"Phase 1a/1b","brief_title":"A Study of TAS-116 in Patients With Solid Tumors","source_id_and_acronym":"NCT02965885","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • ALK translocation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jeselhy (pimitespib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 07/10/2017","start_date":" 07/10/2017","primary_txt":" Primary completion: 05/03/2019","primary_completion_date":" 05/03/2019","study_txt":" Completion: 05/03/2019","study_completion_date":" 05/03/2019","last_update_posted":"2019-10-01"},{"id":"38f7e812-7b2f-4a13-9f7b-f337348cbfb4","acronym":"SARC023","url":"https://clinicaltrials.gov/study/NCT02008877","created_at":"2021-01-18T09:10:25.745Z","updated_at":"2024-07-02T16:36:59.593Z","phase":"Phase 1/2","brief_title":"SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)","source_id_and_acronym":"NCT02008877 - SARC023","lead_sponsor":"Sarcoma Alliance for Research through Collaboration","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • sirolimus • ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2019-05-15"},{"id":"30af6c5b-69c6-4fd7-9cfb-43b1da4df1b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01200238","created_at":"2021-01-18T04:48:32.724Z","updated_at":"2024-07-02T16:37:05.964Z","phase":"Phase 2","brief_title":"STA-9090(Ganetespib) in Metastatic Ocular Melanoma","source_id_and_acronym":"NCT01200238","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MET • HSP90AA1","pipe":" | ","alterations":" MET expression","tags":["MET • HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 09/17/2010","start_date":" 09/17/2010","primary_txt":" Primary completion: 10/12/2014","primary_completion_date":" 10/12/2014","study_txt":" Completion: 11/11/2016","study_completion_date":" 11/11/2016","last_update_posted":"2018-10-18"},{"id":"20b63c84-5fbb-4f76-a357-de7569544623","acronym":"","url":"https://clinicaltrials.gov/study/NCT01922583","created_at":"2021-01-18T08:40:42.278Z","updated_at":"2024-07-02T16:37:08.883Z","phase":"Phase 2","brief_title":"AUY922 in Patient With Stage IV NSCLC","source_id_and_acronym":"NCT01922583","lead_sponsor":"National Taiwan University Hospital","biomarkers":" EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • ALK positive • EGFR T790M • RET fusion • EGFR exon 20 insertion • ALK rearrangement • HER-2 exon 20 insertion • ALK fusion • RET mutation • KIF5B-RET fusion • ALK translocation • EGFR exon 20 mutation • BRAF D594G • BRAF G469A • EGFR A767_V769dup • HER-2 YVMA • TFG-ALK fusion • BRAF exon 15 mutation","tags":["EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • ALK positive • EGFR T790M • RET fusion • EGFR exon 20 insertion • ALK rearrangement • HER-2 exon 20 insertion • ALK fusion • RET mutation • KIF5B-RET fusion • ALK translocation • EGFR exon 20 mutation • BRAF D594G • BRAF G469A • EGFR A767_V769dup • HER-2 YVMA • TFG-ALK fusion • BRAF exon 15 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2018-07-18"},{"id":"59732630-1323-4010-b3db-8aa0e219e383","acronym":"","url":"https://clinicaltrials.gov/study/NCT01246102","created_at":"2021-01-18T08:40:06.980Z","updated_at":"2024-07-02T16:37:09.226Z","phase":"Phase 1","brief_title":"AT13387 in Adults With Refractory Solid Tumors","source_id_and_acronym":"NCT01246102","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HSP90AA1","pipe":"","alterations":" ","tags":["HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e onalespib (AT13387)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 11/19/2010","start_date":" 11/19/2010","primary_txt":" Primary completion: 12/30/2013","primary_completion_date":" 12/30/2013","study_txt":" Completion: 10/27/2017","study_completion_date":" 10/27/2017","last_update_posted":"2018-07-05"},{"id":"368a0113-4719-4eb5-9c5b-b085f9138aa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02060253","created_at":"2021-01-18T09:29:26.595Z","updated_at":"2025-02-25T14:00:25.042Z","phase":"Phase 1","brief_title":"Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer","source_id_and_acronym":"NCT02060253","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2018-06-14"},{"id":"8b190744-a340-4375-8523-8b2ee76f81c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01854034","created_at":"2021-01-18T08:16:50.512Z","updated_at":"2024-07-02T16:37:11.624Z","phase":"Phase 2","brief_title":"Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR","source_id_and_acronym":"NCT01854034","lead_sponsor":"Massachusetts General Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 03/01/2017","primary_completion_date":" 03/01/2017","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2018-04-10"},{"id":"2f2e68f9-1654-40ba-af06-8aa7ed876dca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01752400","created_at":"2021-01-18T07:41:27.772Z","updated_at":"2024-07-02T16:37:12.733Z","phase":"Phase 2","brief_title":"AUY922 for Advanced ALK-positive NSCLC","source_id_and_acronym":"NCT01752400","lead_sponsor":"Massachusetts General Hospital","biomarkers":" KRAS • ALK","pipe":" | ","alterations":" KRAS mutation • ALK translocation","tags":["KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2018-03-29"},{"id":"d66807dc-cc75-441d-8ebe-a286f5e5eb6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01712217","created_at":"2021-01-18T07:27:40.966Z","updated_at":"2024-07-02T16:37:14.689Z","phase":"Phase 1/2","brief_title":"A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib","source_id_and_acronym":"NCT01712217","lead_sponsor":"Astex Pharmaceuticals, Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • onalespib (AT13387)"],"overall_status":"Completed","enrollment":" Enrollment 220","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 05/16/2017","study_completion_date":" 05/16/2017","last_update_posted":"2018-01-19"},{"id":"78a5dedf-4f16-4fbe-a321-02ed38ac3d59","acronym":"","url":"https://clinicaltrials.gov/study/NCT01245218","created_at":"2021-01-18T05:00:54.263Z","updated_at":"2024-07-02T16:37:16.769Z","phase":"Phase 1","brief_title":"AT13387 in Treating Patients With Refractory Solid Tumors","source_id_and_acronym":"NCT01245218","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • HSP90AA1","pipe":"","alterations":" ","tags":["HER-2 • HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e onalespib (AT13387)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 08/01/2011","primary_completion_date":" 08/01/2011","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-31"}]